Abstract
Along years, the advent of biological therapy widely modified treatment
of rheumatic diseases and other disorders. However, many
agents may elicit in anti-drug antibodies (ADAbs) upon consecutive
infusions, with a loss of response. For the right strategy of
a personalized medicine, the therapeutic monitoring of TNF-α inhibitors
and ADAbs represents an important effort in diagnostic–therapeutic
pathway, to improve overall patient management and
favoring an appropriate clinical approach. A raising number of diagnostic
tests have been designed to elucidate the efficacy and/or
safety of a specific drug or class of drugs for a targeted patient’s
group. Our paper reviewed the current understanding of the immunogenicity
of biological drugs employed in the treatment of inflammatory
diseases underlying the laboratory role.
Lingua originale | English |
---|---|
pagine (da-a) | 317-332 |
Numero di pagine | 16 |
Rivista | Immunological Investigations |
Volume | 49 |
DOI | |
Stato di pubblicazione | Pubblicato - 2020 |
Keywords
- TNF
- adalimumab
- anti-TNF drugs
- certolizumab
- immunogenicity